

CURRICULUM VITAE

Education

2007 Ph.D., Department of Biological Science and Technology, Tokyo University of Science, Chiba, Japan

Research Positions

- 2002 Graduate Student, Department of Pathology, National Institute of Infectious Diseases, Tokyo, Japan, in Prof. T. Kurata's lab
- 2007 JSPS Research fellow, Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA, in Prof. A. Iwasaki's lab
- 2009 Assistant Professor, Department of Virology, Faculty of Medicine, Kyushu University, in Prof. Y. Yanagi's lab

ORIGINAL PAPERS / REVIEWS

ORIGINAL PAPERS

18. [Zymosan enhances the mucosal adjuvant activity of poly\(I:C\) in a nasal influenza vaccine.](#)
Ainai A, Ichinohe T, Tamura S, Kurata T, Sata T, Tashiro M, Hasegawa H.
J Med Virol. 2010 Mar;82(3):476-84.
17. [Microbiota regulates immune defense against respiratory tract influenza A virus infection.](#)
Ichinohe T, Pang IK, Kumamoto Y, Peaper D, Ho JH, Murray TS, Iwasaki A.
Proc Natl Acad Sci U S A. 2011 Mar 29;108(13):5354-9.
Comment in. [Nat Rev Immunol.](#) 2011 May;11(5):304-5.
16. [Intranasal administration of adjuvant-combined vaccine protects monkeys from challenge with the highly pathogenic influenza A H5N1 virus.](#)
Ichinohe T, Ainai A, Ami Y, Nagata N, Iwata N, Kawaguchi A, Suzaki Y, Odagiri T, Tashiro M, Takahashi H, Strayer DR, Carter WA, Chiba J, Tamura S, Sata T, Kurata T, Hasegawa H.
J Med Virol. 2010 Oct;82(10):1754-61.
15. [Influenza virus activates inflammasomes via its intracellular M2 ion channel](#)
Ichinohe T, Pang IK, Iwasaki A.
Nature Immunol. 2010 May;11(5):404-10.



14. [Zymosan enhances the mucosal adjuvant activity of poly\(I:C\) in a nasal influenza vaccine.](#)
Ainai A, Ichinohe T, Tamura S, Kurata T, Sata T, Tashiro M, Hasegawa H.
J Med Virol. 2010 Mar;82(3):476-84.

13. [Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.](#)
Ichinohe T, Ainai A, Nakamura T, Akiyama Y, Maeyama J, Odagiri T, Tashiro M, Takahashi H, Sawa H, Tamura S, Chiba J, Kurata T, Sata T, Hasegawa H.
J Med Virol. 2010 Jan;82(1):128-37.
12. [Inflammasome recognition of influenza virus is essential for adaptive immune responses.](#)
Ichinohe T, Lee HK, Ogura Y, Flavell R, Iwasaki A.
J Exp Med. 2009 Jan 16;206(1):79-87.
Comment in. [Expert Rev Vaccines.](#) 2009 Jun;8(6):689-93.
11. [Mechanism of NKT cell activation by intranasal coadministration of alpha-galactosylceramide, which can induce cross-protection against influenza viruses.](#)
Kamijuku H*, Nagata Y*, Jiang X*, Ichinohe T*, Tashiro T, Mori K, Taniguchi M, Hase K, Ohno H, Shimaoka T, Yonehara S, Odagiri T, Tashiro M, Sata T, Hasegawa H, Seino KI.
Mucosal Immunol. 2008 May;1(3):208-18. *These authors contributed equally to this work
Comment in. [Nat Rev Immunol.](#) 2008 Jun;8(6):402-3.
10. [Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine.](#)
Ichinohe T, Tamura S, Kawaguchi A, Ninomiya A, Imai M, Itamura S, Odagiri T, Tashiro M, Takahashi H, Sawa H, Mitchell WM, Strayer DR, Carter WA, Chiba J, Kurata T, Sata T, Hasegawa H.
J Infect Dis. 2007 Nov 1;196(9):1313-20.
9. [Intranasal immunization with H5N1 vaccine plus Poly I:Poly C12U, a Toll-like receptor agonist, protects mice against homologous and heterologous virus challenge.](#)
Ichinohe T, Kawaguchi A, Tamura S, Takahashi H, Sawa H, Ninomiya A, Imai M, Itamura S, Odagiri T, Tashiro M, Chiba J, Sata T, Kurata T, Hasegawa H.
Microbes Infect. 2007 Sep;9(11):1333-40.
8. [Prophylactic effects of chitin microparticles on highly pathogenic H5N1 influenza virus.](#)
Ichinohe T, Nagata N, Strong P, Tamura S, Takahashi H, Ninomiya A, Imai M, Odagiri T, Tashiro M, Sawa H, Chiba J, Kurata T, Sata T, Hasegawa H.
J Med Virol. 2007 Jun;79(6):811-9.
7. [Intranasal administration of adjuvant-combined recombinant influenza virus HA vaccine protects mice from the lethal H5N1 virus infection.](#)
Asahi-Ozaki Y, Itamura S, Ichinohe T, Strong P, Tamura S, Takahashi H, Sawa H, Moriyama M, Tashiro M, Sata T, Kurata T, Hasegawa H.
Microbes Infect. 2006 Oct;8(12-13):2706-14.
6. [Tristetraprolin inhibits HIV-1 production by binding to genomic RNA.](#)
Maeda M, Sawa H, Tobiume M, Tokunaga K, Hasegawa H, Ichinohe T, Sata T, Moriyama M, Hall WW, Kurata T, Takahashi H.
Microbes Infect. 2006 Sep;8(11):2647-56.
5. [Protection against influenza virus infection by intranasal vaccine with surf clam microparticles \(SMP\) as an adjuvant.](#)

Ichinohe T, Watanabe I, Tao E, Ito S, Kawaguchi A, Tamura S, Takahashi H, Sawa H, Moriyama M, Chiba J, Komase K, Suzuki Y, Kurata T, Sata T, Hasegawa H.

J Med Virol. 2006 Jul;78(7):954-63.

4. [Thymus-derived leukemia-lymphoma in mice transgenic for the Tax gene of human T-lymphotropic virus type I.](#)
Hasegawa H, Sawa H, Lewis MJ, Orba Y, Sheehy N, Yamamoto Y, Ichinohe T, Tsunetsugu-Yokota Y, Katano H, Takahashi H, Matsuda J, Sata T, Kurata T, Nagashima K, Hall WW.
Nat Med. 2006 Apr;12(4):466-72.
3. [Synthetic double-stranded RNA poly\(I:C\) combined with mucosal vaccine protects against influenza virus infection.](#)
Ichinohe T, Watanabe I, Ito S, Fujii H, Moriyama M, Tamura S, Takahashi H, Sawa H, Chiba J, Kurata T, Sata T, Hasegawa H.
J Virol. 2005 Mar;79(5):2910-9.
2. [Protection against influenza virus infection by intranasal administration of hemagglutinin vaccine with chitin microparticles as an adjuvant.](#)
Hasegawa H, Ichinohe T, Strong P, Watanabe I, Ito S, Tamura S, Takahashi H, Sawa H, Chiba J, Kurata T, Sata T.
J Med Virol. 2005 Jan;75(1):130-6.
1. [Protection against influenza virus infection by intranasal administration of C3d-fused hemagglutinin.](#)
Watanabe I, Ross TM, Tamura S, Ichinohe T, Ito S, Takahashi H, Sawa H, Chiba J, Kurata T, Sata T, Hasegawa H.
Vaccine. 2003 Nov 7;21(31):4532-8.

REVIEWS

7. [Recognition of viruses by inflammasomes.](#)
Ichinohe T, Yanagi Y.
Fukuoka Igaku Zasshi. 2011 Feb ; 102(2) :21-30.
6. [Respective roles of TLR, RIG-I and NLRP3 in influenza virus infection and immunity: impact on vaccine design.](#)
Ichinohe T
Expert Rev Vaccines. 2010 Nov;9(11):1315-24.
5. [\[Inflammasomes in viral infection\]](#)
Ichinohe T, Iwasaki A.
Uirusu. 2009 Jun;59(1):13-21. Japanese.
4. [PolyI:polyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants.](#)
Ichinohe T, Ainai A, Tashiro M, Sata T, Hasegawa H.
Vaccine. 2009 Oct 23;27(45):6276-9.
3. [Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses.](#)

Hasegawa H, Ichinohe T, Ainai A, Tamura S, Kurata T.
Ther Clin Risk Manag. 2009 Feb;5(1):125-32.

2. [Innate sensors of influenza virus: clues to developing better intranasal vaccines.](#)

Ichinohe T, Iwasaki A, Hasegawa H.
Expert Rev Vaccines. 2008 Nov;7(9):1435-45.

1. [Development of a mucosal vaccine for influenza viruses: preparation for a potential influenza pandemic.](#)

Hasegawa H, Ichinohe T, Tamura S, Kurata T.
Expert Rev Vaccines. 2007 Apr;6(2):193-201.